Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

What was studied

This early trial tested glofitamab with standard immunochemotherapy (G/R-CHOP). Patients had B-cell non-Hodgkin lymphoma that had returned or stopped responding. They had at least 1 earlier course with obinutuzumab or rituximab. The main goal was to find the optimal biological dose of glofitamab. Doses went up in steps, at 70 μg, 1800 μg, 10 mg and 30 mg. Patients had follicular, mantle cell or marginal zone lymphoma.

What they found

The most common side effects were anaemia and fatigue. Many patients had grade 3 or 4 side effects. 4 patients had grade 5 side effects, mostly infections. Many had cytokine release syndrome. In 4 patients it was grade 3 or 4. Most patients had a complete metabolic response. The median time without progression was not reached. Follow-up was 44.2 months.

What it means for patients

The authors say glofitamab with G/R-CHOP showed encouraging benefit. They say this supports further study. The doses to study are 2.5/10/30 mg with R-CHOP. The setting is untreated diffuse large B-cell lymphoma.

Why it is not certain yet

This was an early dose-finding study with no comparison group. Many patients had serious side effects. The median time without progression was not yet reached. So long-term benefit is unclear.

Source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.